Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia
Sponsor: Vogenx, Inc.
Summary
VGX-001-013 (EMERGE) is a Phase 2b study to evaluate an investigational new drug, mizagliflozin, for safety, tolerability and its ability to prevent low blood sugar in patients with post-bariatric hypoglycemia.
Official title: Phase 2B Randomized, Placebo-Controlled, Double-Blind, Repeat Dose Parallel Study in Participants With Post-Bariatric Hypoglycemia to Determine the Effect of Mizagliflozin on Hypoglycemia
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2026-10
Completion Date
2028-01
Last Updated
2026-10-29
Healthy Volunteers
No
Conditions
Interventions
Mizagliflozin 5 mg
5mg mizagliflozin capsules orally administered TID for 28 days
Mizagliflozin 10 mg
10mg mizagliflozin capsules orally administered TID for 28 days
Placebo
Placebo capsules orally administered TID for 28 days
Locations (11)
Exalt Clinical Research
Chula Vista, California, United States
Stanford
Palo Alto, California, United States
U Colorado- Anschutz Medical Campus
Aurora, Colorado, United States
DM Clinical- Miami
Doral, Florida, United States
Georgia Clinical Research
Lawrenceville, Georgia, United States
Centricity Research
Morehead City, North Carolina, United States
Penn Medicine
Philadelphia, Pennsylvania, United States
Vanderbilt Weight Loss Center
Nashville, Tennessee, United States
DM Clinical- Irving
Irving, Texas, United States
UT San Antonio
San Antonio, Texas, United States
Texas Valley Clinical Research
Weslaco, Texas, United States